Stock Groups

AstraZeneca vaccine booster shot effective against Omicron

by Mike Robinson

[ad_1]

© Reuters. FILEPHOTO: A group of people pose in front the AstraZeneca logo. This illustration was taken December 11, 2021. REUTERS/Dado Ruvic/Illustration

(Reuters] – A tri-dose regimen of AstraZeneca’s COVID-19 vaccine against Omicron coronavirus is safe and effective, according to the pharmaceutical company. The data was based on an Oxford University study.

This study was published in peer-reviewed medical journals. It showed that Omicron antibody levels after booster shots were greater than those of people infected by COVID-19 and had recovered from it naturally.

The company said that after a course of three doses of vaccine, Omicron’s neutralizing levels were comparable to the ones against Delta virus following two doses.

Anglo-Swedish pharmaceutical company said that researchers from Oxford University conducted the study independently of those working on Vaxzevria with AstraZeneca.

Disclaimer: Fusion MediaWe remind you that this site does not contain accurate or real-time data. CFDs include stocks, indexes and futures. Prices are provided not by the exchanges. Market makers provide them. Therefore, prices can be inaccurate and differ from actual market prices. These prices should not be used for trading. Fusion Media is not responsible for trading losses that may be incurred as a consequence of the use of this data.

Fusion MediaFusion Media and anyone associated with it will not assume any responsibility for losses or damages arising from the use of this information. This includes data including charts and buy/sell signal signals. You should be aware of all the potential risks and expenses associated with trading in the financial market. It is among the most dangerous investment types.

[ad_2]